Yu Jin Lim1, Kyubo Kim2. 1. Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, 23 Kyungheedae-ro, Dongdaemoon-gu, Seoul, 02447, Republic of Korea. 2. Department of Radiation Oncology, Ewha Womans University College of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul, 07985, Republic of Korea. kyubokim.ro@gmail.com.
Abstract
PURPOSE: The use of adjuvant treatment has not been sufficiently investigated in duodenal adenocarcinoma. This study evaluated the effect of postoperative radiotherapy (PORT) on survival outcomes in this rare malignancy. METHODS: We identified patients who were diagnosed between 2004 and 2013 in the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and disease-specific survival (DSS) were analyzed before and after propensity score matching. RESULTS: Among the 701 eligible patients, 116 (17%) underwent PORT. There were no significant differences in OS and DSS according to receipt of PORT in the unmatched population (P = 0.982 and 0.496, respectively), whereas the propensity-matched analysis showed improved OS and DSS with PORT (P = 0.053 and 0.019, respectively). No receipt of PORT was an independent poor prognostic factor in multivariate analysis of both OS (P = 0.022) and DSS (P = 0.005). The potential survival benefits of PORT were observed in subgroups of T4 stage, larger tumor size, higher lymph node ratio, and total/radical resection. CONCLUSIONS: We provide useful insights into the therapeutic role of PORT in adenocarcinoma of the duodenum. Adjuvant strategy with PORT needs to be considered in locally advanced tumors.
PURPOSE: The use of adjuvant treatment has not been sufficiently investigated in duodenal adenocarcinoma. This study evaluated the effect of postoperative radiotherapy (PORT) on survival outcomes in this rare malignancy. METHODS: We identified patients who were diagnosed between 2004 and 2013 in the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and disease-specific survival (DSS) were analyzed before and after propensity score matching. RESULTS: Among the 701 eligible patients, 116 (17%) underwent PORT. There were no significant differences in OS and DSS according to receipt of PORT in the unmatched population (P = 0.982 and 0.496, respectively), whereas the propensity-matched analysis showed improved OS and DSS with PORT (P = 0.053 and 0.019, respectively). No receipt of PORT was an independent poor prognostic factor in multivariate analysis of both OS (P = 0.022) and DSS (P = 0.005). The potential survival benefits of PORT were observed in subgroups of T4 stage, larger tumor size, higher lymph node ratio, and total/radical resection. CONCLUSIONS: We provide useful insights into the therapeutic role of PORT in adenocarcinoma of the duodenum. Adjuvant strategy with PORT needs to be considered in locally advanced tumors.
Authors: Michael B Nicholl; Vanita Ahuja; W Charles Conway; Vu D Vu; Myung-Shin Sim; Gagandeep Singh Journal: Ann Surg Oncol Date: 2010-05-11 Impact factor: 5.344
Authors: Brett L Ecker; Matthew T McMillan; Jashodeep Datta; Major K Lee; Giorgos C Karakousis; Charles M Vollmer; Jeffrey A Drebin; Douglas L Fraker; Robert E Roses Journal: Cancer Date: 2016-11-07 Impact factor: 6.860
Authors: Michael J Swartz; Michael A Hughes; Deborah A Frassica; Joseph Herman; Charles J Yeo; Taylor S Riall; Keith D Lillemoe; John L Cameron; Ross C Donehower; Daniel A Laheru; Ralph H Hruban; Ross A Abrams Journal: Arch Surg Date: 2007-03
Authors: Susannah Yovino; Matthew Poppe; Salma Jabbour; Vera David; Michael Garofalo; Naimesh Pandya; Richard Alexander; Nader Hanna; William F Regine Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-14 Impact factor: 7.038
Authors: Brett L Ecker; Matthew T McMillan; Jashodeep Datta; Ronac Mamtani; Bruce J Giantonio; Daniel T Dempsey; Douglas L Fraker; Jeffrey A Drebin; Giorgos C Karakousis; Robert E Roses Journal: Cancer Date: 2015-12-30 Impact factor: 6.860
Authors: F G Bakaeen; M M Murr; M G Sarr; G B Thompson; M B Farnell; D M Nagorney; D R Farley; J A van Heerden; L M Wiersema; C D Schleck; J H Donohue Journal: Arch Surg Date: 2000-06
Authors: Edwin O Onkendi; Sarah Y Boostrom; Michael G Sarr; Michael B Farnell; David M Nagorney; John H Donohue; Michael L Kendrick; Kaye M Reid-Lombardo; William S Harmsen; Florencia G Que Journal: J Gastrointest Surg Date: 2012-02-17 Impact factor: 3.452
Authors: Kulbir Mann; T Gilbert; S Cicconi; R Jackson; P Whelan; F Campbell; C Halloran; J Neoptolemos; P Ghaneh Journal: Langenbecks Arch Surg Date: 2019-04-10 Impact factor: 3.445